NCT07174427招募中3 期
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Objective response rate
研究概览
简要总结
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age
- •Histologically confirmed synovial sarcoma
- •Surgically unresectable tumor
- •Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of systemic chemotherapies including anthracycline
- •HLA-A*02:01 or HLA-A*02:06 positive
- •Tumor that express NY-ESO-1 by immunohistochemistry
- •Measurable lesions that are evaluable by the RECIST ver1.1
- •ECOG Performance Status of 0, 1 or 2
- •No treatment such as chemotherapy and be expected to recover fully from the previous treatment at the time of the lymphocytes collection for manufacturing
- •Life expectancy ≥ 16 weeks after consent
- •No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc) and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(GOT), ALT(GPT) < 3.0 x ULN; Creatinine < 1.5 x ULN; 2,500/μL < WBC ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL
- •Patients must be able to understand the study contents and to give a written consent at his/her free will.
排除标准
- •Patients with the following conditions are excluded from the study; Unstable angina, cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active autoimmune disease requiring steroids or immunosuppressive therapy.
- •Active metastatic tumor cell invasion into CNS
- •Active multiple cancer
- •Positive for HBs antigen or HBV-DNA observed in serum
- •Positive for HCV antibody and HCV-RNA observed in serum
- •Positive for antibodies against HIV or HTLV-1
- •History of serious hypersensitivity reactions to bovine or murine derived substances.
- •History of hypersensitivity reaction to ingredients or excipients of investigational drugs used in this study
- •History of hypersensitivity reaction to antibiotics used in manufacturing for the investigational drug used in this study.
- •History of treatment with cell therapy or gene therapy
- •Alcohol or drug dependence that may interfere with study participation
- •Pregnant females, lactating females (except when they cease and do not resume lactation) or female and male patients who cannot agree to practice the adequate birth control from the consent to 6 months after infusion of the investigational drug.
- •Clinically significant systemic illness that in the judgment of the PI or sub-investigator would compromise the patient's ability to tolerate protocol therapy or significantly increase the risk of complications.
研究组 & 干预措施
Split dose of 5x10^9 TBI-1301
Experimental
Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following pre-treatment for 2 days.
干预措施: TBI-1301 (Biological)
Split dose of 5x10^9 TBI-1301
Experimental
Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following pre-treatment for 2 days.
干预措施: Fludarabine (Drug)
Split dose of 5x10^9 TBI-1301
Experimental
Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following pre-treatment for 2 days.
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Objective response rate
时间窗: 52 weeks
Evaluate response rate by measuring response using RECIST v1.1
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial SarcomaSynovial SarcomaNCT03250325Takara Bio Inc.8
进行中（未招募）
1 期
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsNY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsLung CancerOvarian CancerMelanomaBladder CancerLiver CancerEsophageal CancerSynovial SarcomaNCT02869217University Health Network, Toronto22
已完成
1 期
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in SarcomaBone SarcomaSoft Tissue SarcomaNCT03462316Sun Yat-sen University2
招募中
1 期
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersSarcoma, SynovialSarcoma,Soft TissueMelanoma Stage IVTriple Negative Breast CancerMetastatic CancerNon Small Cell Lung CancerBladder Urothelial CarcinomaNeuroblastoma, MetastaticOvary CancerNCT05296564Hadassah Medical Organization3
已完成
1 期
Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial SarcomaSynovial sarcomaJPRN-jRCT1080223459Takara Bio Inc.8